Powder: -20°C for 3 years | In solvent: -80°C for 1 year
Quisovalimab (AVTX-002; AEVI 002; SAR 252067), a human monoclonal antibody targeting LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14), is crucial for managing acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) in COVID-19. This compound has potential applications in treating ARDS related to COVID-19 and is subject to ongoing research [1].
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
5 mg | Inquiry | Inquiry |
Description | Quisovalimab (AVTX-002; AEVI 002; SAR 252067), a human monoclonal antibody targeting LIGHT, a tumor necrosis factor (TNF)-related cytokine (TNFSF14), is crucial for managing acute respiratory distress syndrome (ARDS) and cytokine release syndrome (CRS) in COVID-19. This compound has potential applications in treating ARDS related to COVID-19 and is subject to ongoing research [1]. |
Molecular Weight | N/A |
CAS No. | 2427667-03-4 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
Quisovalimab 2427667-03-4 inhibitor inhibit